YEM Search

搜索结果

靶点ID:TCMBANKGE005811

靶点别名:EDH17B2; HSD17; SDR9C2

靶点描述:hydroxysteroid 17-beta dehydrogenase 2

染色体:16

染色体位置:16q23.3

靶点类型:protein-coding

HERB_ID:HBTAR001930

HGNC_Link:5211

OMIM_Link:109685

Ensembl_Link:ENSG00000086696

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN029162	18beta-glycyrrhetinic acid	AJ-72559; Rhetinic Acid; C02283; GLYCYRRHETINIC ACID; 18-beta-Glycyrrhetinic acid; 1449-05-4; Glycyrrhetic acid; Hidermart; CHEMBL230006; SMR000058239; SR-01000721867-5; NCGC00142473-03; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); UNII-P540XA09DR; Enoxolone (Glycyrrhetin); 107420-91-7; Enoxolone, Glycyrrhetinic acid; CCRIS 3962; LMPR0106150014; 18beta-Glycyrrhetic acid; 4-10-00-03775 (Beilstein Handbook Reference); BB_NC-0599; HMS2233P23; LS-7417; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; Opera_ID_1048; D0U8IF; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; NSC-35350; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); AC-1925; Glycyrrhetinic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; HY-N0180; Arthrodont; Hidermart (TN); DTXSID9020669; SR-01000721867-3; MLS002207101; Enoxolona; Glycyrrhetinic acid (JAN); A-Hydroxy-11-oxoolean-12-en-30-olic acid; SR-01000721867-6; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; subglycyrrhelinic acid; SCHEMBL18540; 471-53-4; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; BG01168029; FT-0082445; BX-1; Glycyrrhetin; D00156; NCGC00017244-03; 202522-39-2; 18-beta-Glycyrrhetic acid; SR-01000721867-4; Enoxolonum [INN-Latin]; SBB006496; GM-1658; Q-201057; NSC-35347; NSC 35347; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; alpha-Glycyrrhetinic acid; Tox21_112726; 130100-EP2295411A1; ZINC19203131; Biosone; D08LGJ; Bio-0549; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid; Enoxolone (Glycyrrhetinic acid); 50510_FLUKA; BDBM50233538; Uralenic acid; NCGC00017244-04; P540XA09DR; 18beta-glycyrrhetic acid; C30H46O4; Jintan; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; CAS-471-53-4; Tox21_200799; SR-01000721867; Enoxolone (INN); MLS001146949; MLS000028748; [(125)I] RB129; G10105_ALDRICH; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; s2296; CCG-208506; 8055-71-8; EINECS 207-444-6; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Enoxolona [INN-Spanish]; GlycyrrhetinicAcid; 18b-Glycyrrhetic acid; AC1L1UIT; 130100-EP2269977A2; KS-1262; Glycyrrhetinate; Glycyrrhetinic acid [JAN]; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; BC201656; Enoloxone; Enoxolone [INN:BAN:DCF]; 18 beta-glycyrrhetinic acid; 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; enoxolone; DSSTox_RID_75722; 18 beta-Glycyrrhetintic Acid; DSSTox_CID_669; 3-Glycyrrhetinic acid; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; NCGC00181115-01; Enoxolone; STX-352; AKOS016036757; 15301-63-0; G0149; MFCD00003706; ST24038257; Enoxolone, European Pharmacopoeia (EP) Reference Standard; ST056310; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-13-keto-2,4a,6a,6b,9,9,12a-heptamethyl-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; AKOS015960428; 471G534; NCGC00258353-01; DB13089; Tox21_110804; CBW; DSSTox_GSID_20669; D0F6IV; MolPort-002-507-130; A827163; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18beta-Glycyrrhetinic acid, 97%; CHEBI:30853; AC-8906; AN-14462; API0002854; BRN 2229654; Glyciram; 18beta-Glycyrrhetinic acid; MCULE-4676598997; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; BG00824432; Enoxolone [BAN:DCF:INN]; CS-W020624; S00284; Enoxolonum; 299198-00-8	C30H46O4	470.68	CC1(C2CCC3(C(C2(CCC1O)C)C(=O)C=C4C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C
TCMBANKIN058213	kaemferol;kampferol;kaempferol;campherol	TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-	C15H10O6	286.24 g/mol	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
TCMBANKIN058990	forskolin	coleonol	C22H34O7	410.5 g/mol	CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O
TCMBANKIN060110	oestrone		C18H22O2	270.4 g/mol	CC12CCC3C(C1CCC2=O)CCC4=C3C=CC(=C4)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000166		-	-	Neoplastic Process	disease
TCMBANKDI006612		Neoplasms; Female Urogenital Diseases and Pregnancy Complications	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI011743		Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI020257		Cardiovascular Diseases	-	Disease or Syndrome	disease
TCMBANKDI020602		Male Urogenital Diseases	Abnormality of the genitourinary system	Disease or Syndrome	disease
TCMBANKDI025420		Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI030540		Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI031192		Neoplasms; Male Urogenital Diseases	-	Neoplastic Process	disease